PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35549996-3	2022	Treatment with sodium-glucose co-transporter-2 (SGLT2) inhibitors, such as empagliflozin, is a novel therapy that reduces 1,5-anhydroglucitol (1,5AG) in plasma.	1,5-anhydroglucitol	122-141	solute carrier family 5 member 2	Homo sapiens	15-46	
35549996-3	2022	Treatment with sodium-glucose co-transporter-2 (SGLT2) inhibitors, such as empagliflozin, is a novel therapy that reduces 1,5-anhydroglucitol (1,5AG) in plasma.	1,5-anhydroglucitol	122-141	solute carrier family 5 member 2	Homo sapiens	48-53	
32838757-3	2020	Recently, SGLT2 inhibitors such as empagliflozin that reduce the plasma levels of 1,5-anhydroglucitol have been described as a new treatment option for the neutropenia and neutrophil dysfunction in patients with GSD Ib.	1,5-anhydroglucitol	82-101	solute carrier family 5 member 2	Homo sapiens	10-15	
32904185-0	2020	1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 diabetes mellitus.	1,5-anhydroglucitol	0-19	solute carrier family 5 member 2	Homo sapiens	72-102	
32904185-12	2020	Conclusion: The use of SGLT2 inhibitors in patients with T2DM, 1,5-AG was identified as the most reliable indicator for predicting HbA1c reduction.	1,5-anhydroglucitol	63-69	solute carrier family 5 member 2	Homo sapiens	23-28